Illumina launches compact, low-cost gene sequencing devices
Adds shares and analyst comments in paragraphs 4-5
By Puyaan Singh and Bhanvi Satija
Oct 9 (Reuters) -Medical equipment maker Illumina ILMN.O announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to make sequencing accessible to more research and testing labs.
New generation sequencers, like Illumina's MiSeq devices, help determine the sequence of DNA or RNA to study genetic variation associated with diseases and diagnose rare genetic conditions.
Unlike Illumina's NovaSeq X devices — which are as large as a Xerox copier and designed for in-depth sequencing — the new MiSeq i100 systems can be placed on benchtops, allowing smaller labs, which typically outsource gene sequencing, to have these capabilities in-house.
However, the company's shares were down 1.3%. "Instead of a revolutionary development, the instrument looks more like evolutionary development based on technology in the NovaSeq X platform that has been reworked," said Morningstar analyst Julie Utterback.
"Relative to investor expectations, today's announcement did not meet the bar," said Evercore ISI analyst Vijay Kumar.
The U.S. list price for the NovaSeq X devices starts at just under $1 million compared to the MiSeq i100, which is priced at $49,000.
The i100 Plus system, designed to process a greater number of samples, has a list price of $109,000.
The new MiSeq devices can produce results in just four hours, four times faster than the older MiSeq sequencer that is priced at $99,000.
CEO Jacob Thaysen stated that the new sequencers represent a billion-dollar opportunity for Illumina.
MiSeq i100 devices will offer 18 different programs accessible on the instrument and in the cloud.
These include panels for detecting respiratory and urinary pathogens, conducting influenza A and B surveillance, and utilizing multiple cancer research panels.
The San Diego-based company said it is taking pre-orders for the systems and will start shipping them globally in 2025.
Illumina said the reagents used in these devices can be shipped and stored at room temperature, eliminating the need for costly and bulky freezers.
Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru; Editing by Tasim Zahid and Alan Barona
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
